|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choudhary C, Kumar C, Gnad F, Nielsen ML,
Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation
targets protein complexes and co-regulates major cellular
functions. Science. 325:834–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Venugopal B and Evans TR: Developing
histone deacetylase inhibitors as anti-cancer therapeutics. Curr
Med Chem. 18:1658–1671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dovey OM, Foster CT and Cowley SM: Histone
deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell
differentiation. Proc Natl Acad Sci USA. 107:8242–8247. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Delcuve GP, Khan DH and Davie JR:
Targeting class I histone deacetylases in cancer therapy. Expert
Opin Ther Targets. 17:29–41. 2013. View Article : Google Scholar
|
|
6
|
Weichert W, Röske A, Gekeler V, Beckers T,
Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of
patterns of class I histone deacetylase expression with patient
prognosis in gastric cancer: A retrospective analysis. Lancet
Oncol. 9:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang JC, Kafeel MI, Avezbakiyev B, Chen C,
Sun Y, Rathnasabapathy C, Kalavar M, He Z, Burton J and Lichter S:
Histone deacetylase in chronic lymphocytic leukemia. Oncology.
81:325–329. 2011. View Article : Google Scholar
|
|
8
|
Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li
H, Zhou L, Han YN, Wu KC, Nie YZ, et al: MicroRNA-296–5p increases
proliferation in gastric cancer through repression of
Caudal-related homeobox 1. Oncogene. 33:783–793. 2014. View Article : Google Scholar
|
|
9
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar
|
|
11
|
Buurman R, Gürlevik E, Schäffer V, Eilers
M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F and
Skawran B: Histone deacetylases activate hepatocyte growth factor
signaling by repressing microRNA-449 in hepatocellular carcinoma
cells. Gastroenterology. 143:811–20.e1. 152012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Toh HC, Chow P, Chung AY, Meyers
DJ, Cole PA, Ooi LL and Lee CG: MicroRNA-224 is up-regulated in
hepatocellular carcinoma through epigenetic mechanisms. FASEB J.
26:3032–3041. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mims A, Walker AR, Huang X, Sun J, Wang H,
Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, et
al: Increased anti-leukemic activity of decitabine via
AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting
approach in acute myeloid leukemia. Leukemia. 27:871–878. 2013.
View Article : Google Scholar :
|
|
14
|
Chakraborty S, Mazumdar M, Mukherjee S,
Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A
and Das T: Restoration of p53/miR-34a regulatory axis decreases
survival advantage and ensures Bax-dependent apoptosis of non-small
cell lung carcinoma cells. FEBS Lett. 588:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
LeBoeuf M, Terrell A, Trivedi S, Sinha S,
Epstein JA, Olson EN, Morrisey EE and Millar SE: Hdac1 and Hdac2
act redundantly to control p63 and p53 functions in epidermal
progenitor cells. Dev Cell. 19:807–818. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu
B, Pan S, Dong X, Tan G, Wei Z, et al: Inhibition of Akt reverses
the acquired resistance to sorafenib by switching protective
autophagy to autophagic cell death in hepatocellular carcinoma. Mol
Cancer Ther. 13:1589–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao D, Zhai B, He C, Tan G, Jiang X, Pan
S, Dong X, Wei Z, Ma L, Qiao H, et al: Upregulation of HIF-2α
induced by sorafenib contributes to the resistance by activating
the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell
Signal. 26:1030–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei Z, Jiang X, Liu F, Qiao H, Zhou B,
Zhai B, Zhang L, Zhang X, Han L, Jiang H, et al: Downregulation of
Skp2 inhibits the growth and metastasis of gastric cancer cells in
vitro and in vivo. Tumour Biol. 34:181–192. 2013. View Article : Google Scholar
|
|
19
|
Naor D, Nedvetzki S, Golan I, Melnik L and
Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scott GK, Mattie MD, Berger CE, Benz SC
and Benz CC: Rapid alteration of microRNA levels by histone
deacetylase inhibition. Cancer Res. 66:1277–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Izzotti A, Cartiglia C, Steele VE and De
Flora S: MicroRNAs as targets for dietary and pharmacological
inhibitors of mutagenesis and carcinogenesis. Mutat Res.
751:287–303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao J, Lammers P, Torrance CJ and Bader
AG: TP53-independent function of miR-34a via HDAC1 and
p21CIP1/WAF1. Mol Ther. 21:1678–1686. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nalls D, Tang SN, Rodova M, Srivastava RK
and Shankar S: Targeting epigenetic regulation of miR-34a for
treatment of pancreatic cancer by inhibition of pancreatic cancer
stem cells. PLoS One. 6:e240992011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeng SS, Yamashita T, Kondo M, Nio K,
Hayashi T, Hara Y, Nomura Y, Yoshida M, Hayashi T, Oishi N, et al:
The transcription factor SALL4 regulates stemness of EpCAM-positive
hepatocellular carcinoma. J Hepatol. 60:127–134. 2014. View Article : Google Scholar
|
|
25
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen
Q, Leng W, Chen L, Tang Q and Bi F: CD44 acts through RhoA to
regulate YAP signaling. Cell Signal. 26:2504–2513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zöller M: CD44: Can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sumoza-Toledo A and Santos-Argumedo L: The
spreading of B lymphocytes induced by CD44 cross-linking requires
actin, tubulin, and vimentin rearrangements. J Leukoc Biol.
75:233–239. 2004. View Article : Google Scholar
|
|
29
|
Lin MT, Lin BR, Chang CC, Chu CY, Su HJ,
Chen ST, Jeng YM and Kuo ML: IL-6 induces AGS gastric cancer cell
invasion via activation of the c-Src/RhoA/ROCK signaling pathway.
Int J Cancer. 120:2600–2608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McConnell BV, Koto K and
Gutierrez-Hartmann A: Nuclear and cytoplasmic LIMK1 enhances human
breast cancer progression. Mol Cancer. 10:752011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murphy G and Nagase H: Progress in matrix
metalloproteinase research. Mol Aspects Med. 29:290–308. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hanna S and El-Sibai M: Signaling networks
of Rho GTPases in cell motility. Cell Signal. 25:1955–1961. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Struckhoff AP, Rana MK and Worthylake RA:
RhoA can lead the way in tumor cell invasion and metastasis. Front
Biosci. 16:1915–1926. 2011. View
Article : Google Scholar
|
|
34
|
Kim Y, Lee YS, Choe J, Lee H, Kim YM and
Jeoung D: CD44-epidermal growth factor receptor interaction
mediates hyaluronic acid-promoted cell motility by activating
protein kinase C signaling involving Akt, Rac1, Phox, reactive
oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem.
283:22513–22528. 2008. View Article : Google Scholar : PubMed/NCBI
|
